PharmaCyte Biotech 8-K: Shareholder Vote Matters Reported
Ticker: PMCB · Form: 8-K · Filed: May 1, 2024 · CIK: 1157075
| Field | Detail |
|---|---|
| Company | Pharmacyte Biotech, Inc. (PMCB) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
TL;DR
PharmaCyte Biotech filed an 8-K on shareholder vote matters. Standard corporate governance.
AI Summary
PharmaCyte Biotech, Inc. filed an 8-K on May 1, 2024, reporting on matters submitted to a vote of security holders as of April 29, 2024. The filing details the company's principal executive offices located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada, 89169, and its principal business address in Laguna Hills, California. The company was incorporated in Nevada and its fiscal year ends on April 30.
Why It Matters
This filing indicates that PharmaCyte Biotech, Inc. is engaging in corporate governance activities, specifically submitting matters for a vote by its shareholders, which is a standard but important procedural step for public companies.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing shareholder vote matters and company addresses, with no immediate financial or operational risks indicated.
Key Players & Entities
- PharmaCyte Biotech, Inc. (company) — Registrant
- April 29, 2024 (date) — Date of earliest event reported
- May 1, 2024 (date) — Date of report
- 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 (address) — Principal Executive Offices
- 23046 Avenida de la Carlota, Suite 600 Laguna Hills, CA 92653 (address) — Business Address
- Nevada (jurisdiction) — State of incorporation
FAQ
What specific matters were submitted to a vote of PharmaCyte Biotech's security holders?
The filing states that the report is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and concerns 'Submission of Matters to a Vote of Security Holders'. However, the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 29, 2024.
What is PharmaCyte Biotech, Inc.'s principal executive office address?
PharmaCyte Biotech, Inc.'s principal executive office is located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169.
In which state was PharmaCyte Biotech, Inc. incorporated?
PharmaCyte Biotech, Inc. was incorporated in Nevada.
What is the company's fiscal year end date?
The company's fiscal year ends on April 30.
Filing Stats: 643 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-01 16:05:13
Key Financial Figures
- $0.0001 — h registered Common Stock , Par Value $0.0001 Per Share PMCB The Nasdaq Stock Ma
Filing Documents
- pharmacyte_8k.htm (8-K) — 32KB
- 0001683168-24-002881.txt ( ) — 202KB
- pmcb-20240429.xsd (EX-101.SCH) — 3KB
- pmcb-20240429_lab.xml (EX-101.LAB) — 33KB
- pmcb-20240429_pre.xml (EX-101.PRE) — 22KB
- pharmacyte_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On April 29, 2024, PharmaCyte Biotech, Inc. (the "Company") held its annual meeting of stockholders for the year ended April 30, 2024 (the "Annual Meeting") via live webcast. At the Annual Meeting, 4,514,887 shares of common stock, or approximately 53.41% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum. At the Annual Meeting, the stockholders of the Company voted as set forth below on three proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2024. The final voting results for each matter submitted to a vote of the Company's stockholders are as follows: Proposal 1. Election of Directors. The election of five directors, each to hold office until the annual meeting of stockholders for the year ended April 30, 2025 or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Joshua N. Silverman 1,892,894 266,539 2,355,454 Jonathan L. Schechter 2,064,472 94,961 2,355,454 Michael M. Abecassis 1,579,782 579,651 2,355,454 Robert Weinstein 2,022,363 137,070 2,355,454 Wayne R. Walker 2,060,785 98,648 2,355,454 Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the board of directors of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2024. For Against Abstain 4,387,273 109,167 18,447 Proposal 3. Approval of Executive Compensation. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. For Against Abstain Non-Votes Broker Non-Votes 1,922,352 186,215 50,866 0 2,355,454 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 1, 2024 PHARMACYTE BIOTECH, INC. By: /s/ Joshua N. Silverman Name: Joshua N. Silverman Title: Interim Chief Executive Officer and Interim President 3